

---

**A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy**

**Grant Award Details**

---

A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

**Grant Type:** Clinical Trial Stage Projects

**Grant Number:** CLIN2-08280

**Project Objective:** Phase III trial completed

**Investigator:**

<b>Name:</b>	Anthony Gringeri
<b>Institution:</b>	ImmunoCellular Therapeutics
<b>Type:</b>	PI

---

**Disease Focus:** Brain Cancer, Cancer, Solid Tumors

**Human Stem Cell Use:** Cancer Stem Cell

**Award Value:** \$5,391,016

**Status:** Closed

**Grant Application Details**

---

**Application Title:** A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

**Public Abstract:**            **Therapeutic Candidate or Device**

Autologous dendritic cells pulsed with HLA-specific peptides derived from tumor-associated antigens

**Indication**

Newly diagnosed glioblastoma

**Therapeutic Mechanism**

Autologous dendritic cells charged with peptides derived from tumor-associated antigens drive the formation of T cells that specifically target cancer stem cells and tumor cells

**Unmet Medical Need**

Patients with glioblastoma, a rare brain cancer with orphan status, have a poor prognosis and limited lifespan despite current standard of care. Treatment options are limited to surgery, radiotherapy and a single chemotherapeutic agent. Tumor stem cells are resistant to current standard of care.

**Project Objective**

Phase III trial completed

**Major Proposed Activities**

- Manufacture autologous therapeutic product for each patient in the Phase III trial
- Conduct a multi-center, international Phase III clinical trial showing conclusive safety and efficacy of ICT-107 for newly diagnosed glioblastoma

**Statement of Benefit to California:**

Glioblastoma is a deadly orphan disease whose patients have a dire prognosis, limited lifespan, and few therapeutic options. Over a thousand patients annually are diagnosed with glioblastoma in California. If ICT-107 proves effective in this Phase III trial, it will lead to increased survival, better quality of life, and potential cures many of these patients. Furthermore, success of the dendritic cell-based immunotherapy in this trial could lead to similar treatments for other tumor types.

---

**Source URL:** <https://www.cirm.ca.gov/our-progress/awards/phase-iii-randomized-double-blind-controlled-study-ict-107-maintenance>